Partner News | Published: Friday, July 22, 2022
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, is excited to announce its industry partnership with Daxor Corporation, the global leader in blood volume measurement technology focused on blood volume testing innovation.
“Daxor’s technology helps ensure providers are able to prescribe the right treatment at the right time. With heart failure diagnosis continuing to increase, access to accurate blood volume testing will transform the way care decisions are made,” said Joe Sasson, PhD, MedAxiom’s EVP of Ventures. “We are proud to welcome Daxor as a MedAxiom Industry Partner and bring their innovative solutions to our membership community.”
The Daxor Corporation developed and markets the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the U.S. Food and Drug Administration (FDA). The BVA-100 provides 98% accurate testing that is safe and reimbursable, with quantification of blood volume status and composition compared to patient-specific norms. Their testing is the most precise method to quantify volume status quickly and efficiently so care teams have individualized and actionable results achievable within one hour.
"You will not only find out the fluid status of your patient immediately with blood volume analysis, but also learn more about heart failure in general and the different fluid phenotypes that have caused you trouble in the past," said Isaac Rhea, M.D., Cardio-Oncology, MedAxiom Member Hospital.
A peer-reviewed study published in the Journal of the American College of Cardiology-Heart Failure demonstrated significantly improved outcomes with BVA-guided treatment: 82% reduction in 30-day mortality, 86% reduction in 365-day mortality, 56% reduction in 30-day readmissions, and three-day reduction in hospital length of stay with 16% of the cohort being discharged on day one.
"We look forward to partnering with MedAxiom, the leader in organizational performance solutions in the cardiology space, with an unparalleled network of members and expertise. Together we will improve the lives of patients and reduce the burden of heart failure for clinicians and hospital systems by raising awareness and adoption of Daxor's unique blood volume analysis technology," said Michael Feldschuh, President and CEO of Daxor.
Data presented at the Heart Failure Society of America Annual Scientific Meeting 2020 studied the economic benefits of the use of blood volume analysis in the population of heart failure patients, one of the largest cost-drivers of the national healthcare system. The data showed an "extremely cost-effective" incremental cost-effectiveness ratio of $10,200 which was 80% less costly than other therapies that are considered "good value" by common quality metrics. The data also revealed an average life-extension of 2.32 quality-adjusted life years in addition to the cost savings.
MedAxiom, an ACC Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of 450+ cardiovascular organization members, thousands of administrators, clinicians and coders and 40+ industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.
For additional information, visit MedAxiom.com.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. Daxor manufactures the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status to help guide optimal fluid management. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor's vision is optimal blood volume for all.
For additional information, visit Daxor.com.